Nuvation Bio Inc (NUVB)
Featured in
High-Beta Stocks
Nuvation Bio Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for cancer. Its lead candidate is IBTROZI (taletrectinib), a ROS1 inhibitor being developed for patients with ROS1-positive non-small cell lung cancer. The company is also advancing safusidenib, a mutant IDH1 inhibitor that is in phase 3 clinical testing for maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma, compared with placebo. Nuvation Bio was founded in 2018 and is headquartered in New York, New York. The company’s common stock trades on the New York Stock Exchange under the symbol NUVB.
Stock Summary
Fair Value
Profitability & Growth
Quality & Risk
Events & Dividends
Technical Outlook
FAQ
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NYSE-NUVB
|
$5.79
|
-10.0% Downside
|
Fair
|
$12.33
|
91.7% Upside
|
Bargain
|
Good
|
—
|
—
|
—
|
0.0%
|
August 6, 2026
|
-15.4x
|
7.0x
|
15.7x
|
2.18 B
|
1.933 B
|
9.1%
|
73.1%
|
2.3
|
—
|
86.3%
|
